Increasingly, drugs in this category are no longer defined by GLP1 activity alone and target multiple hormones
it is backed by science and biochemistry
A classic deficit-creation combination less in, more out using two complementary natural mechanisms
Novera KLOW is manufactured according to strict quality-control procedures intended to support consistency between production batches
The choice of route aims to balance effect size, convenience, and side-effect risk
The following adverse effects were reported in patients receiving semaglutide injection or oral tablets across all clinical trials and at incidences higher than with placebo: nausea (11% to 44%), vomiting (5% to 24%), diarrhea (8.5% to 30%), abdominal pain (5.7% to 20%), abdominal distention (2% to 7%), constipation (3.1% to 24%), dyspepsia (0.6% to 9%), decreased appetite (6% to 9%), eructation (0.6% to 7%), flatulence (0.4% to 6%), gastroesophageal reflux disease (1.5% to 5%), gastroenteritis (4% to 6%), and gastritis (0.4% to 4%)